论文部分内容阅读
目的观察TX方案(多西他赛+希罗达)和TP方案(多西他赛+顺铂)治疗蒽环类药物耐药乳腺癌的临床效果。方法蒽环类药物耐药的乳腺癌患者50例随机均分为TP方案化疗(A)组和TX方案化疗(B)组。观察两组患者的近期疗效、远期生存率和不良反应。结果治疗结束后2个月,A组完全缓解率为16.0%,客观有效率为60.0%,略高于B组的12.0%和56.0%(P>0.05)。随访3年。A组和B组的1、2和3年生存率相仿(62.5%vs.60.9%、37.5%vs.30.4%和20.8%vs.17.4%)(P>0.05)。两组不良反应主要表现为骨髓抑制、胃肠道反应和手足综合征,经对症治疗均好转。结论 TX方案和TP方案治疗蒽环类耐药乳腺癌均有良好疗效,不良反应可耐受。
Objective To observe the clinical effect of TX (docetaxel + xeloda) and TP (docetaxel + cisplatin) on anthracycline-resistant breast cancer. Methods Fifty patients with anthracycline-resistant breast cancer were randomly divided into two groups: TP regimen (group A) and TX regimen (group B). Short-term efficacy, long-term survival and adverse reactions were observed in both groups. Results Two months after the end of treatment, the complete remission rate in group A was 16.0%, the objective effective rate was 60.0%, slightly higher than that in group B (12.0% vs 56.0%, P> 0.05). Followed up for 3 years. The 1-, 2-, and 3-year survival rates in groups A and B were similar (62.5% vs.60.9%, 37.5% vs.30.4% and20.8% vs.17.4%, respectively) (P> 0.05). Two groups of adverse reactions mainly manifested as bone marrow suppression, gastrointestinal reactions and hand-foot syndrome, symptomatic treatment were improved. Conclusion Both TX and TP regimens are effective in treating anthracycline-resistant breast cancer, and adverse reactions are tolerable.